ELI LILLY COO: ZYPREXA SALES DOWN GLOBALLY, WILL HURT 2Q

A A

Eli Lilly & Co. (LLY) Chief Operating Officer John C. Lechleiter said Thursday that sales of the company's drug Zyprexa are down, which will have an impact on the company's second quarter. Earlier Thursday, the pharmaceutical company posted first-quarter results that beat analyst expectations on strong Cymbalta sales, which doubled in the U.S. and globally this quarter compared to a year earlier.
Therapeutics Daily